Renewal season is here, and employers are reevaluating their health insurance offerings with one topic heavy on their minds: GLP-1 coverage. It is no surprise that GLP-1 demand continues to rise as their weight-loss benefits are all over the news and social media.

While the public may view these drugs as a silver bullet solution, there is also a cloud of potential misinformation regarding who should use them, possible side effects, and other long-term risks and successes. As employers navigate whether to begin or continue covering GLP-1s for obesity, they also need to consider how they will support and educate their workforce about appropriate indications and uses. These considerations include when to begin taking GLP-1s, access to clinical support during treatment, and oversight when discontinuing use.